N6,2′-O-Dimethyladenosine

N6,2′-O-Dimethyladenosine is a FTO substrate and reversible RNA modification. N6,2′-O-Dimethyladenosine acts as a demethylation substrate for FTO, which removes its methyl groups. N6,2′-O-Dimethyladenosine correlates with enhanced mRNA stability, improved translation efficiency and increased protein expression levels. N6,2′-O-Dimethyladenosine is applicable to research related to obesity and colorectal cancer^[1][2]. In Vitro:Endogenous N6,2′-O-Dimethyladenosine (m6Am) modification on transcripts from Mettl3 knockout mouse embryonic stem cells correlates with increased mRNA stability, translation efficiency, and higher protein expression^[1].
N6,2′-O-Dimethyladenosine, via the m6AmPred model built with XgbDart and EIIP-PseEIIP encoding, accurately identifies N6,2′-O-dimethyladenosine (m⁶A_m) sites on HEK293 cell-derived full transcript and mature RNA sequences, achieving up to 0.958 AUC_0-t via 10-fold cross-validation for mature RNA sequences^[2]. In Vivo:N6,2′-O-Dimethyladenosine modification is dynamically reduced in high-fat diet-induced obese mice, with loss of m6Am associated with significant downregulation of target gene mRNA and protein expression, including key metabolic genes like FABP2 and FABP5^[1].
N6,2′-O-Dimethyladenosine modification is dynamically regulated in genetically obese ob/ob mice, with loss of m6Am associated with downregulated target gene mRNA and protein expression, and gain of m6Am associated with upregulated expression^[1].